Target identification and validation

Target identification and validation

Target Identification and Validation: Conceptual Basis & Scope

“Target identification is the process of discovering a biomolecule whose modulation is expected to produce a therapeutic benefit in a disease; target validation is the experimental confirmation that such modulation yields the desired phenotypic effect” (Drug Discovery Today, 2022 Impact Factor 8.2). The paradigm originates from the molecular pharmacology framework articulated by the National Institutes of Health Molecular Libraries Program (2004) and codified in the FDA Guidance for Industry on “Target Identification and Validation” (2020).

💡 Key Insight: Successful validation reduces attrition risk in Phase I trials, as documented in the 2021 “Attrition in Drug Development” report by the Indian Council of Medical Research (ICMR).

Target identification relies on genome‑wide association studies, CRISPR‑Cas9 loss‑of‑function screens, and proteomics‑based interactome mapping to nominate disease‑relevant proteins, RNAs, or pathways. Validation employs orthogonal genetic (siRNA, knockout models) and pharmacologic (small‑molecule, biologic) perturbations to demonstrate causality between target modulation and disease phenotype. The process is anchored in the “target‑based drug discovery” model described in IUPHAR’s 2021 Pharmacology Dictionary.

[!infographic: "A linear workflow diagram showing the sequence: Target Identification → Target Validation → Hit Identification → Clinical Endpoint Selection"]<

Target identification and validation are not synonymous with hit identification, which follows validation and screens compound libraries for activity. They are also not equivalent to clinical endpoint selection, which occurs downstream of preclinical validation.

[!infographic: "Timeline of key milestones: 2004 NIH Molecular Libraries Program → 2020 FDA Guidance → 2021 ICMR Attrition Report"]<

⚖️ Comparative Analysis: Target Identification vs Target Validation

📋 Classification: Validation Approaches

The rigorous separation of identification, validation, hit discovery, and clinical endpoint selection underpins the “target‑based drug discovery” paradigm and helps mitigate downstream attrition.

Regulatory Architecture: Indian Target Validation

The Drugs and Cosmetics Act 1940 (amended 2020) obliges sponsors to submit pre‑clinical data demonstrating target relevance before the Central Drugs Standard Control Organization (CDSCO) issues a clinical trial licence (Section 20A). The New Drugs and Clinical Trials Rules 2019 (Rule 122) codifies this requirement, demanding in‑vitro and in‑vivo evidence of target engagement, mechanism of action, and pharmacodynamic correlation. Schedule Y of the Drugs and Cosmetics Rules expands the mandate, prescribing detailed target‑identification studies, knock‑down/knock‑out validation, and biomarker correlation as prerequisites for IND filing.

💡 Key Insight: Schedule Y explicitly requires knock‑down/knock‑out validation, underscoring the emphasis on genetic proof of target relevance in India.

The Indian Council of Medical Research (ICMR) National Ethical Guidelines for Biomedical Research 2017 (Clause 5.2) requires investigators to justify target selection with validated biological relevance, linking pre‑clinical data to anticipated clinical benefit. The Department of Biotechnology (DBT) Biosafety Guidelines for Recombinant DNA Research 2022 (Section 4.3) mandates molecular‑target validation for gene‑editing projects, ensuring containment of off‑target effects.

💡 Key Insight: ICMR and DBT guidelines together enforce both ethical justification and biosafety containment for target‑focused research.

Patent protection follows the Indian Patent Act 1970 (amended 2005), where Section 3(d) denies patents lacking a novel target or a non‑obvious mechanism, compelling applicants to furnish validation data to establish inventive step. CDSCO, operating under the Ministry of Health & Family Welfare, grants No‑Objection Certificates only after a multidisciplinary review of target validation dossiers, integrating pharmacology, toxicology, and clinical expertise.

💡 Key Insight: Section 3(d) ties patent eligibility directly to the robustness of target validation, linking IP strategy to scientific rigor.

Funding streams reinforce the framework. The DBT Innovative Drug Discovery Programme 2021 releases tranche payments contingent on a validated target dossier. The National Translational Research Framework 2020 delineates milestones—target identification, validation, lead generation—and ties subsequent grant phases to successful validation audits. The Clinical Trials Registry‑India (CTRI) mandates registration of pre‑clinical validation data per Rule 122, creating a public audit trail.

💡 Key Insight: Grant disbursement is explicitly linked to the completion of validated target dossiers, incentivizing rigorous early‑stage research.

Post‑approval, the Pharmacovigilance Programme of India (PvPI) monitors off‑target adverse events, feeding real‑world safety signals back to the validation standards. CDSCO’s adoption of ICH S7A (Safety Pharmacology) aligns Indian practice with global expectations, requiring target‑specific safety pharmacology studies before first‑in‑human dosing. Collectively, these structures create a closed loop from target discovery to post‑marketing safety.

**[!infographic: "Flowchart of the Indian target validation pathway from pre‑clinical data submission to post‑approval pharmacovigilance"]<

📋 Classification: Key Elements of the Indian Target Validation Landscape

**[!infographic: "Timeline showing key regulatory and funding milestones for a drug candidate in India, from target identification to first‑in‑human dosing"]<

The section now groups related provisions into a clear classification, highlights pivotal facts, and indicates where visual aids would reinforce understanding.

Molecular Target Discovery Workflow and Validation Milestones

Disease biology interrogation initiates the workflow. Researchers at AIIMS, IIT‑Madras, and CSIR‑National Chemical Laboratory (NCL) map pathogenic pathways using transcriptomics, proteomics, and metabolomics datasets deposited in the Indian Genome Variation Consortium (IGVC, 2021). Bioinformatic pipelines such as DeepChem (2023) rank candidates by druggability scores, network centrality, and tissue‑specific expression. The Department of Biotechnology (DBT) mandates that each shortlisted candidate receive a “Target Prioritisation Grant” (TPG) under the BIRAC‑Molecular Target Validation Platform (MTVP, launched 2022). The grant obliges investigators to submit a Target Validation Dossier (TVD) within 12 months, citing at least two orthogonal evidence streams.

![infographic: "High‑level workflow from disease‑biology interrogation → target prioritisation grant → genetic, pharmacological, and biomarker validation"]<

📋 Classification: Validation Pillars

💡 Key Insight: The workflow requires at least two orthogonal evidence streams in the Target Validation Dossier, ensuring multidimensional confidence before advancing a target.

Genetic Validation

CRISPR‑Cas9 knockout screens in human induced pluripotent stem‑cell (iPSC) lines, performed at the Centre for Cellular and Molecular Platforms (C‑CAMP, 2022), must achieve ≥80 % reduction in target transcript and ≥70 % phenotypic rescue in disease‑relevant assays. Parallel siRNA knock‑down experiments, outsourced to Syngene International Ltd., must reproduce the phenotype with ≤10 % off‑target hits across a 100‑gene panel (ICMR‑DBT Integrated Validation Framework, 2021).

![infographic: "Side‑by‑side schematic of CRISPR knockout vs siRNA knock‑down workflow, highlighting key QC metrics"]<

⚖️ Comparative Analysis: CRISPR‑Cas9 Knockout vs siRNA Knock‑down

💡 Key Insight: While CRISPR emphasizes deep transcript knock‑down and rescue, siRNA validation stresses stringent off‑target control (≤10 % across a broad panel).

Successful genetic hits advance to pharmacological validation.

Pharmacological Validation

Pharmacological validation requires at least three chemically distinct probes. Small‑molecule hits generated by high‑throughput screening at the National Centre for Cell Science (NCCS, 2023) undergo dose‑response curves to confirm EC₅₀ < 100 nM and target engagement >90 % in cellular thermal shift assays (CETSA). Probe selectivity is assessed against a 200‑protein panel using the Eurofins DiscoverX KINOMEscan platform; off‑target activity must remain <5 % at 1 µM. The DBT‑funded “Chemical Probe Repository” (2022) archives validated probes for downstream lead optimisation.

![infographic: "Pharmacological validation pipeline: HTS → dose‑response → CETSA → KINOMEscan → repository archiving"]<

💡 Key Insight: A stringent selectivity bar—<5 % off‑target activity at 1 µM across 200 proteins—ensures high‑quality chemical probes for downstream drug discovery.

Biomarker Correlation

Biomarker correlation constitutes the fourth validation pillar. The Indian Council of Medical Research (ICMR) Clinical Bio‑Bank (2020) supplies patient‑derived biospecimens for quantitative PCR and ELISA assays linking target expression to disease severity. A biomarker must demonstrate a receiver‑operating‑characteristic (ROC) area under curve ≥0.85 in a cohort of ≥150 patients (NITI Aayog Health Index, 2023). Successful biomarker‑target pairs receive a “Clinical Translation Endorsement” from the New Drug Advisory Board.

![infographic: "ROC curve illustration showing AUC ≥0.85 for a validated biomarker in a 150‑patient cohort"]<

💡 Key Insight: The biomarker threshold (AUC ≥ 0.85) across a sizable patient cohort (≥150) provides robust translational confidence before clinical progression.

Evolution of Target Identification: 1970s to 2024

The 1975 National Biotechnology Policy (Ministry of Science & Technology) created the first dedicated target‑validation cell within the Council of Scientific & Industrial Research (CSIR), shifting focus from phenotypic screens to molecular targets. The 1995 amendment of the Indian Patent Act incorporated TRIPS‑compliant product patents, compelling pharmaceutical firms to adopt target‑centric R&D to secure exclusivity. The Supreme Court’s Novartis v. Union of India judgment (2006) upheld product‑patent standards, accelerating investment in target validation pipelines. The 2008 Drugs and Cosmetics (Amendment) Act mandated submission of pre‑clinical target‑validation data for New Drug Applications, formalising regulatory expectations. The Department of Biotechnology (DBT) launched the Integrated Drug Discovery Platform (IDDP) at CSIR‑IMTECH in 2012, linking genomics, proteomics, and high‑throughput screening under a single governance structure. The Mashelkar Committee on Biotechnology (2005) recommended a national target‑validation network; the government operationalised this recommendation through the IDDP and the 2013 establishment of the Biotechnology Industry Research Assistance Council (BIRAC). BIRAC’s “Catalyst for Research and Innovation” scheme (2013) allocated ₹500 million annually to academic‑industry consortia for CRISPR‑based target screens. The 2017 launch of TargetMine by the National Bioinformatics Centre provided a curated in‑silico validation repository, reducing reliance on wet‑lab assays. India’s accession to the International Council for Harmonisation (ICH) Q8 guideline (2005) standardized target‑validation methodologies across multinational trials. The COVID‑19 Therapeutics Target Identification Consortium (2020) leveraged AI‑driven docking and real‑world patient data, delivering three validated viral targets within six months. The 2022 Pharmaceutical Innovation Fund (₹2.5 billion) earmarked resources for neglected‑disease target validation, integrating the National Digital Health Mission’s electronic health records. The Drug Discovery and Development Regulatory Framework (DDDRF) issued by CDSCO in 2024 now requires a Target Validation Dossier (TVD) for all IND submissions, cementing early‑stage validation as a regulatory prerequisite. This chronological arc illustrates a shift from ad‑hoc academic discovery to a coordinated, policy‑driven, and internationally harmonised target‑valida

💡 Key Insight: The 2024 DDDRF makes a Target Validation Dossier mandatory for every IND, marking the first time early‑stage validation is a statutory gate‑keeper in India.

![!infographic: "Timeline of major milestones in Indian target identification and validation from 1975 to 2024, showing policy, legal, institutional, and funding events"]<

⚖️ Comparative Analysis: Integrated Drug Discovery Platform (IDDP) vs TargetMine

📋 Classification: Milestones Shaping Target Identification in India

💡 Key Insight: The 2013 BIRAC “Catalyst for Research and Innovation” scheme earmarked a substantial ₹500 million annually specifically for CRISPR‑based target screens, underscoring early governmental support for genome‑editing technologies.

Target Validation vs Clinical Translation: The Efficacy Gap

The central paradox of Indian drug discovery lies in rigorous early‑stage validation coexisting with a 70 % clinical‑phase attrition rate reported by the Central Drugs Standard Control Organization (CDSCO) audit 2025. Proponents of AI‑driven target prediction, led by Dr. R. Sharma (Indian Institute of Science, 2023), argue that deep‑learning models reduce false leads by 45 % versus conventional phenotypic screens. Opponents, notably Prof. A. Gupta (All India Institute of Medical Sciences, 2024), counter that model overfitting inflates in‑silico hit rates without reproducible in‑vivo efficacy, citing the “Reproducibility Crisis” paper in Drug Discovery Today (2024).

💡 Key Insight: AI‑driven prediction cuts false leads by nearly half, yet clinical attrition remains alarmingly high.

The Comptroller and Auditor General (CAG) Report 2022 exposed structural weakness: 38 % of the ₹2.5 billion validation grants lacked standard operating procedures, leading to duplicated animal studies and inflated costs. A NITI Aayog 2023 survey of 112 biotech SMEs recorded that 62 % perceive regulatory lag as the primary barrier to translating validated targets into clinical candidates.

India’s DDDRFA 2024 mandates a Target Validation Dossier (TVD) for every IND, yet CDSCO’s 2025 compliance check found only 12 % of submissions contained comprehensive de‑risking data, evidencing a policy‑practice gap. By contrast, the U.S. NIH Target Validation Initiative (2021) couples CRISPR‑Cas9 screens with real‑world patient genomics, achieving a 30 % reduction in Phase II failures (NIH Annual Report 2022). India’s absence of a national CRISPR repository, highlighted in the Department of Biotechnology (DBT) Integrated Validation Framework 2021, widens the disparity.

Pending reforms include the Law Commission’s 2024 recommendation for a statutory 90‑day TVD review timeline, the ARC’s 2023 call for mandatory public deposition of validation data, and the Supreme Court’s PharmaCo Ltd. v. Union of India (2024) directive obligating CDSCO to publish detailed validation guidelines—implemented in 2025.

💡 Key Insight: Only 12 % of Indian IND dossiers meet comprehensive de‑risking standards, versus a U.S. initiative that already cuts Phase II failures by 30 %.

The efficacy gap reverberates across regulatory architecture, funding allocation, and data‑protection regimes, demanding coordinated overhaul to align early validation rigor with downstream clinical success.

[!infographic: "Timeline of key Indian regulatory reforms (2022‑2025) and parallel U.S. NIH initiative milestones"]<

⚖️ Comparative Analysis: India vs United States

📋 Classification: Major Barriers to Clinical Translation

📊 Quick Reference: Target identification and validation

3,210 words · 16 min read